Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR), a Singapore-based biomedical and biotechnology firm focused on chronic wound management, infertility solutions, and cosmeceuticals, has announced the completion of a laboratory by its 49%-owned associate, Cuprina MENA Co. Ltd, in Saudi Arabia. This lab will produce MEDIFLY maggot debridement therapy for chronic wound treatment and serve the entire Middle East and North Africa (MENA) region.
Cuprina MENA is currently pursuing regulatory approvals, including the Saudi Food and Drug Authority license and ISO 13485 certification, to commercialize the therapy in the MENA region.
Additionally, Cuprina MENA has secured exclusive rights from Biopharm UK Ltd (BioPharm), a leading medicinal leech provider, to market these leeches across the Gulf Cooperation Council (GCC) countries.
Medicinal leeches are increasingly used in the GCC to treat conditions like venous congestion and to support tissue healing and circulation after reconstructive and microsurgery. They are also used for osteoarthritis symptom relief and in veterinary surgery, particularly for treating polycythaemia vera, a chronic blood cancer.
Cuprina CEO David Quek stated that the completion of these milestones will expand the company’s market reach in the MENA and GCC regions and generate significant incremental revenue. He anticipates providing further updates soon.
About Cuprina Holdings (Cayman) Limited
We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https://
About Biopharm UK Ltd
BioPharm is an international company based in Hendy, South Wales, UK. Established originally in 1812, it moved to its current base in 1984. BioPharm is the first leech farm of its kind and we are innovators in the cultivation of the medicinal leech, currently producing the majority of leeches used in modern medicine worldwide.
BioPharm is the pioneer in medical leech provision and has nurtured the renaissance of leeches in modern surgery. Our leeches are maintained in as sterile and pure environment as is possible; we continually invest in technology which includes ultraviolet light sterilization, reverse osmosis, activated carbon absorption and foam fractionating. These processes ensure that BioPharm Leeches are of the highest clinical standard. For more information, please visit
FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email:
Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email:
“`
